Collaboration overview
Daewoong pharma invested $104.6m to HANALLL biopharma and co-managing together for developing new growth engine to be global top pharmaceutical company.
Benefits to Daewoong Pharma
- Gain HANALL’s cutting edge purification technology and mass product-able special purifying system such as infusion solution plant.
- Gain multi-advanced R&D pipelines including developing anti-body origin technology and glucose down OR technology
Benefits to partners
- Successful out-licensing deal has done via strategic collaboration between two companies by focusing on our own strength (Daewoong R&D 50%, HANALL R&D 50%)
- 2017 HanAll granted Roivant an exclusive license for worldwide of HL161
- 2017 HanAll granted Harbour BioMed an exclusive license in China of HL161 & HL0036